[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

GILD

Gilead Sciences sees a surge in social media buzz, driven by strong Q3 earnings and pipeline developments, though concerns linger over oncology performance.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines.

Insights

gild posts created is up XXXXX% from the previous week.

Engagements: XXXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXX
Daily Average: XXXXXXX
X Week: XXXXX -XX%
X Month: XXXXXX -XX%
X Months: XXXXXXXXXX -XX%
X Year: XXXXXXXXXX +120%
1-Year High: XXXXXXXXX on 2025-04-28
1-Year Low: X on 2025-11-17

Engagements by network (24h): Reddit: XX TikTok: XXXXX X: XXXXX YouTube: XXXXX

Mentions: XX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXX -XX%
X Months: XXXXXX -XX%
X Year: XXXXXX -X%
1-Year High: XXXXX on 2025-06-27
1-Year Low: X on 2025-11-17

Mentions by network (24h): Reddit: X TikTok: XXX X: XXX YouTube: XX

Creators: XX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning GILD in the last XX hours which is up XX% from XX in the previous XX hours Daily Average: XXX
X Week: XXX -XX%
X Month: XXX -XX%
X Months: XXXXXX +103%
X Year: XXXXXX +178%
1-Year High: XXXXX on 2025-06-27
1-Year Low: X on 2025-11-17

The most influential creators that mention GILD in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@IEberley95897	X		X	XX

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XXX% no change
X Month: XXX% +33%
X Months: XXX% +33%
X Year: XXX% +22%
1-Year High: XXX% on 2025-10-31
1-Year Low: XX% on 2025-11-03

Most Supportive Themes:

Positive Earnings Report: (40%) Gilead Sciences reported strong Q3 2025 earnings, exceeding revenue and EPS expectations, driven by its HIV franchise and liver disease treatments.
Pipeline and Partnership Milestones: (30%) The company highlighted robust pipeline advancements and strategic partnerships, contributing to a positive outlook.
HIV Franchise Strength: (20%) Continued momentum in the HIV portfolio, with Biktarvy sales increasing by 6%, underscores a key growth driver for Gilead.

Most Critical Themes:

Oncology Weakness and Declines: (70%) Despite overall positive results, there are concerns regarding the declining performance in cell therapy and a slowdown in Trodelvy growth.
Veklury Sales Decline: (30%) Veklury sales have seen a significant year-over-year decrease, a trend expected to continue post-pandemic normalization.